🧬ErlySign Secures ₹16 Crore in Pre-Series A Round to Revolutionize Oral Cancer Detection 💰🩺 Founded by Shubhendra Singh Thakur and Deovrat Begde in Nagpur, ErlySign, formerly known as CURO BIOSCIENCES PRIVATE LIMITED, has raised ₹16 crore in a pre-Series A funding round led by investor Ashish Kacholia. ErlySign has developed a salivary biomarker-based test that detects oral precancerous conditions in just 15 minutes. This non-invasive, rapid test helps identify early signs of oral cancer, providing an affordable and pain-free alternative to traditional diagnostic procedures. The funding, guided by Boutique Advisers Private Wealth & DerivativeSaint, will fast-track the development of the startup’s innovative oral cancer detection kit🧬💡 Why ErlySign Matters: 🎯 1) Innovation in Healthcare: ErlySign’s test is quick, affordable, and highly effective, revolutionizing early cancer detection for oral cancer. 💉 2) High Accuracy: The test boasts 100% specificity and 98.04% sensitivity, ensuring a reliable diagnostic tool. ✅🔬 3) Global Potential: With patents secured in India and the U.S., ErlySign is positioned for global expansion, addressing the growing need for accessible cancer testing. 🌍📈 4) Future Growth: Beyond oral cancer, ErlySign plans to leverage CRISPR miRNA-based technology to test for multiple types of cancer from a single saliva sample. 🧬🧪 With strong backing, ErlySign is poised to revolutionize cancer diagnostics, offering a simple, fast, and reliable solution that could save lives by detecting cancer early. The funding will drive R&D and global expansion, improving healthcare access for millions. 🌟🔍 #ErlySign #CancerDetection #HealthcareInnovation #OralCancer #News #AI #EarlyDiagnosis #Diagnostics #CRISPR #HealthCare #Startups #Cancer #IndianStartups #StartupNews #Tech #HealthcareStartups #FundingNews #Hypes Start Big, Start Here.
Hypes.in’s Post
More Relevant Posts
-
Healthtech Startup 4baseCare Secures $6 Million to Revolutionize Cancer Care Solution Indian healthcare sector, healthtech startup 4baseCare has announced securing $6 million in Series A funding led by Yali Capital. The investment will be instrumental in expanding the company’s innovative cancer care solutions and bolstering its global footprint. Founded in 2018 by Hitesh Goswami and Kshitij Rishi, 4baseCare has been at the forefront of leveraging genomics and digital health technology to provide precision oncology solutions. The company’s focus on developing tailored treatment plans based on individual genetic makeup has shown promising results in improving patient outcomes. With this fresh infusion of capital, 4baseCare plans to augment its product offerings, establish genomics laboratories in key markets like the Philippines, Nepal, and Dubai, and expand its reach across Asia and the Middle East. The company aims to democratize access to advanced cancer care by making its solutions affordable and accessible to a wider patient population. Mathew Cyriac, Founding General Partner at Yali Capital, expressed enthusiasm about the investment, stating, “The genomics landscape in cancer care presents a massive opportunity to create impactful businesses while improving countless lives. 4baseCare’s ability to enhance genomic tests with data from underrepresented populations is particularly impressive.” 4baseCare’s innovative approach and demonstrated impact on over 10,000 cancer patients in Southeast Asia have garnered significant attention from the healthcare industry. The company’s experienced leadership team and strong advisory board further solidify its position as a frontrunner in the precision oncology space. As 4baseCare continues to grow and expand, it is poised to become a key player in transforming cancer care globally. #startup #startupnews #business #healthcare #tech #4baseCare #yali #company #investment #funds #funding #raising #cancer #solution #post
-
-
Cancer focused biotech startup Immuneel Therapeutics Pvt. Ltd. has raised Rs 100 crore from TAIBA Middle East FZ LLC. 💰 This marks the company’s fourth Series A round after raising $11 million in 2019, $1.4 million in 2020, and $15 million in 2022 from investors including F-Prime Capital, Khosla Ventures, and Eight Roads Ventures. The round appears to be ongoing. Immuneel Therapeutics was founded in 2018 by Biocon founder Kiran Mazumdar Shaw, Pulitzer Prize winner Siddhartha Mukherjee, and Kush Parker. The Bengaluru-based startup aims to make CAR-T cell therapy commercially available to patients in India at affordable prices and is developing the country’s first Phase 2 trial for CD19 CAR-T(IMN-003A) for B cell malignancies (Leukemia & Lymphoma). Read more at the link in our comments section below 👇 #FundingWithYS #Funding #Startups
-
-
Helping Early Healthtech Startup raise $1-3M Funding in 90 Days | Award Winning Serial Entrepreneur | Best-Selling Author
At 13, Surbhi Sarna faced a life-changing cancer scare. At 24, she turned that into a company which sold for $275 million. As a young teen, Sarna was diagnosed with complex ovarian cysts. She endured intense pain and uncertainty for many years, spending her best years in hospitals instead of outside with her friends. One of the biggest problems she faced was inconclusive results from diagnostic tools, leaving women like her with limited options beyond invasive surgery. Sarna decided to change this - and made it her life’s mission to transform ovarian cancer diagnostics. She pursued a career in medtech, founded nVision Medical, and after many years of innovation - had a breakthrough. Her team developed the first FDA-cleared microcatheter for collecting cells from the fallopian tubes, improving early detection of ovarian cancer. But the road to success was far from easy. She was: - Rejected by over 50 investors - Doubted because she didn’t have an MBA - Ignored because she wasn’t a medical doctor But Sarna kept trying, till she raised $16 million in venture capital and led her company through successful clinical trials. Six years later, in 2018, Boston Scientific acquired nVision Medical for $275 million, validating her vision. Now, she’s a Partner at Y Combinator, investing in and mentoring biotech and healthcare startups. I find Surbhi Sarna’s journey so inspiring. She faced a personal struggle, realised it was universal - and helped millions by finding a better solution. What did you think of her story? #entrepreneurship #healthtech #innovation
-
-
𝐌𝐚𝐤𝐢𝐧𝐠 𝐏𝐫𝐞𝐜𝐢𝐬𝐢𝐨𝐧 𝐎𝐧𝐜𝐨𝐥𝐨𝐠𝐲 𝐢𝐧 𝐑𝐮𝐫𝐚𝐥 𝐈𝐧𝐝𝐢𝐚 𝐀 𝐑𝐞𝐚𝐥𝐢𝐭𝐲 In the era of precision oncology, advancements like molecular profiling and targeted therapies are transforming cancer care globally. However, accessibility to these cutting-edge technologies remains a significant challenge in rural regions of India. At Homi Bhabha Cancer Hospital and Research Center, Muzaffarpur, Bihar, we embarked on a journey to overcome these barriers, conducting a prospective observational study from #November 2022 to #December 2023. Despite resource constraints, integrating next-generation sequencing (#NGS) with precision medicine in a rural setting proved transformative, offering personalized treatment plans for patients across diverse cancer types. This milestone is a testament to the power of #collaboration, #cooperation and #consensus and determination to make precision oncology accessible for all. 💡 Let’s continue to pave the way for #equitable cancer care across India, one step at a time. #PrecisionOncology #NGS #CancerCare #MolecularProfiling #RuralHealthcare #InnovationInHealthcare #Healthcare #CancerResearch #NGS #Equity #startup #CEO #Bihar #GOI Government of Bihar #HealthTech
-
-
🌟 Startup Mentor & Consultant | Empowering Entrepreneurs | Nurturing Dreams into Reality 🌟
#GranzaBio #BreakthroughTherapies - Celebrating the innovation and advancements in cancer treatment that have the potential to save countless lives. #PioneeringScience - Honoring the groundbreaking research and collaboration in the field of oncology and immunology that Granza Bio is spearheading. #HopeForHealing - Reflecting the hope and promise that new therapies bring to patients battling cancer and other diseases. #PrecisionMedicine - Highlighting the focus on developing targeted therapies that ensure treatments are delivered precisely where they are needed most. #GlobalImpact - Emphasizing the far-reaching effects of Granza Bio’s work, from their roots in India to making a global impact in healthcare innovation. 4o
Oxford-based biotech startup Granza Bio, co-founded by Indian doctors Dr Ashwin Nandakumar and Dr Ashwin Jainarayanan, has secured over $7.14 million in seed funding to develop a groundbreaking cancer therapy. The startup, co-founded with renowned immunologist Professor Michael Dustin, is using the power of "attack particles" – the immune system's natural weapons against diseases like cancer, autoimmunity, and infections. By developing a precision delivery system for these particles, Granza Bio aims to transform the treatment of cancer and other diseases. “We are developing a series of precision delivery shells that can encompass and direct any therapeutic cargo to the correct destination in our body,” Dr Ashwin Nandakumar told biospace. Dr Nandakumar, CEO of Granza Bio, holds a PhD in Oncology and has previously set up clinical trials, while Dr Jainarayanan, CSO, has a PhD in Interdisciplinary Bioscience. Their collaboration with Prof Dustin, a leading expert in the field, has resulted in a powerful team dedicated to developing life-saving therapies. The fresh funding from investors including Felicis, Refactor, Y Combinator, and angel investors will accelerate Granza Bio's research and development efforts, bringing them closer to clinical trials and ultimately, to patients in need. #cancertherapy #seedfunding #healthcare #innovation #Kerala #Chennai [cancer therapy, medical research, Granza Bio, Dr Nandakumar, Dr Jainarayanan]
-
-
#startupnews #fundingalert Karna D Shinde Invests in Navaux for Cancer Detection Innovation Karna D. Shinde, a strategic investor known for his investments in health tech and innovative startups, has invested in Navaux, a company at the forefront of cancer detection technology. Navaux has developed a breakthrough blood test that detects early-stage cancer by identifying the protein Hepsin, which is produced by tumor cells. This innovative approach aims to provide a simple and effective method for early cancer detection, potentially revolutionizing the healthcare industry. Navaux's technology promises to make early cancer detection more accessible and less invasive, significantly improving patient outcomes. The investment from Karna D. Shinde will enable Navaux to further develop its technology, expand its market reach, and enhance its research and development efforts. Shinde's strategic insight and financial support are expected to play a crucial role in accelerating Navaux's growth and success in the healthcare sector. #HealthTech #CancerDetection #Innovation #EarlyDetection #HealthcareRevolution #KarnaShinde #Navaux #Investment #TechForGood #HealthcareInnovation #MedicalBreakthrough #Biotech #CancerResearch #StartupSuccess #PatientCare #LifeSciences #FutureOfHealthcare #EarlyIntervention #MedicalTechnology #Oncology
-
Seattle Immunotherapy Startup Umoja Biopharma Raises $100M https://lnkd.in/gqJC7qFg Another Seattle-area health startup is raising a big new round of funding. Umoja Biopharma announced a $100 million Series C round that will help the Seattle-based company further develop its CAR T-cell immunotherapy treatments for cancer. Umoja is developing a multi-pronged technology that retools a patient’s immune system in vivo, or within a living organism, to generate cancer-fighting cells inside the body. The company launched in 2019 and is working to commercialize technology developed at Seattle Children’s Research Institute and Purdue University. Its headquarters are in Seattle, and it has a manufacturing operations site in Colorado. The post Seattle Immunotherapy Startup Umoja Biopharma Raises $100M appeared first on Life Science Washington . Click here to view original post Click Here to Publish/Feature Your Company or Product News with Biotech Networks
-
ExSURE PVT. LTD., an innovative biotech startup revolutionizing cancer treatment, has successfully raised Rs 3 crore in a seed funding round led by Unicorn India Ventures! Founded in 2021 by Swastika Paul and Abhishek Dutta, Exsure is focused on reducing the side effects and toxicity of anti-cancer drugs using a cutting-edge exosome-based drug delivery platform. This technology targets both cancer and cancer stem cells, aiming to improve the quality of life for patients and minimize chemotherapy’s toxic effects. The fresh funds will help Exsure complete its non-clinical studies, expand its global reach, and support the promotion of key products like Exosure, Leucosure, PlantExosure, and Dr. Berries. With fivefold growth in the past fiscal year, Exsure is on track to service 50+ clients this year and has been selected for the OIST Innovation Accelerator Program in Japan! The Indian biotech sector is on track to reach $150 billion by 2025, and Exsure is well-positioned to be a major player in this booming industry. Read More: https://lnkd.in/gCXU69hq #Exsure #SeedFunding #Biotech #CancerTreatment #ExosomeTechnology #Innovation #HealthTech #Startups #Biotechnology #CancerResearch #R&D #GlobalExpansion #OISTInnovationAccelerator #UnicornIndiaVentures
-
Barcelona-based startup Sycai Medical raises €3 Million led by LUMO Labs and Ship2B Ventures to improve early diagnosis of cancer in the abdomen https://lnkd.in/duXQXfKk
